Merck KGaA (OTCMKTS:MKKGY) Short Interest Up 710.0% in February

Merck KGaA (OTCMKTS:MKKGYGet Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 8,100 shares, an increase of 710.0% from the February 13th total of 1,000 shares. Based on an average daily volume of 238,300 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Merck KGaA Stock Down 0.1 %

Shares of MKKGY traded down $0.04 during trading on Friday, reaching $29.11. The company’s stock had a trading volume of 66,769 shares, compared to its average volume of 124,004. Merck KGaA has a twelve month low of $27.68 and a twelve month high of $39.17. The company has a fifty day moving average of $29.28 and a two-hundred day moving average of $31.72. The company has a quick ratio of 0.91, a current ratio of 1.33 and a debt-to-equity ratio of 0.28. The company has a market cap of $18.81 billion, a price-to-earnings ratio of 17.97, a P/E/G ratio of 2.05 and a beta of 0.98.

Merck KGaA (OTCMKTS:MKKGYGet Free Report) last posted its quarterly earnings results on Thursday, March 6th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.07. Merck KGaA had a return on equity of 10.41% and a net margin of 12.89%. The company had revenue of $5.78 billion during the quarter, compared to analysts’ expectations of $5.40 billion. On average, sell-side analysts predict that Merck KGaA will post 1.87 EPS for the current fiscal year.

Merck KGaA Company Profile

(Get Free Report)

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

Recommended Stories

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.